the-infoshop.com - The vertical markets research portal
View CartView Cart
Global Information, Inc.
US: +1-860-674-8796
EU: +32-2-535-7543
SG: +65-6223-2436
  Home | Catalog | E-mail Alert | Custom Research | About The Infoshop | Contact Us | Site Map |

* View All Categories
Japanese Korean Chinese

[Report]

Commercial Insight: Multiple Sclerosis Continued growth makes the MS market a highly attractive investment

Published: 2007/06

Contact 24 hrs/day
Table of Contents

Abstract

Overview

Introduction

The dynamic MS market continues to grow unabated; seven major market revenues increased 14.7% from 2005 to $4.6 billion in 2006. Growth is driven by the highly successful beta-interferon brands, Teva' s Copaxone (glatiramer acetate), and the recent relaunch of Tysabri; the first launch of a new MS treatment for six years.

Scope

  • This report focuses on the leading disease-modifying therapies used to treat MS, with seven major market (7MM) sales and volume forecasts to 2016
  • Assessment of current and future opportunities and threats in the MS market across the 7MMs
  • Future market events that are expected to affect drug revenues are discussed and quantified for each of the 7MMs
  • Lifecycle management case studies show how previously successful strategies should be applied in the current and future MS market

Report Highlights

Despite the comparatively large MS population, the UK only accounted for 1.1% of the 7MM total in 2006. Datamonitor believes the UK has potential to be a much more profitable and attractive MS market. If treatment rates were on par with Germany, the UK market could have been worth $293m in 2006-almost six times higher than the actual value.

In order to successfully position a new drug class in the market, future market players must have a clear and focused marketing strategy. With Copaxone-launched in 1997-Teva has set the benchmark, and by utilizing similar tactics, future MS players can successfully position novel therapies in the market.

There remains a large opportunity for current and future players to cement and develop their positions in the MS market. To ensure continued revenue and to minimize franchise risk companies can follow Biogen Idec' s strategy to market two or more products and show commitment to the MS community through long-term franchise investment.

Reasons to Purchase

  • Assess the impact of events such as patent expiries and new product launches on the sales of key marketed brands
  • Quantify the future size of the MS market, in terms of volume and value, in each of the 7MM
  • Identify key lifecycle management strategies that can ensure growth in the competitive MS market
Table of Contents

[Report]
Commercial Insight: Multiple Sclerosis Continued growth makes the MS market a highly attractive investment
Published: 2007/06
Published by : Datamonitor Datamonitor

Price:
US $ 15,200.00 PDF by E-mail (Single User License)
>
Product Code : DC53178
Please inform me when related publications are released
InfoWatch

Available 24 Hours a Day
US: 1-860-674-8796 EU: 32-2-535-7543 SG: 65-6223-2436
The vertical markets research portal
© 2008, the-infoshop.com by Global Information, Inc. All rights reserved.